InfuSystem Holdings to Report Q3 2026 Results November 3 Before Market Open

InfuSystem Holdings (INFU) will report Q3 2026 results on November 3 before market open. An investor call is scheduled for 9:00 a.m. ET the same day, with a replay available until February 3, 2027.

Original reporting
Published Oct 27, 2026, 10:33 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 27, 2026, 10:43 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
InfuSystem Holdings to Report Q3 2026 Results November 3 Before Market Open — source image
Decision brief

The 30-second read

$INFUNeutralLow
01

Why it matters

The filing is a routine earnings‑date announcement, providing limited new information for traders.

02

Market read

The news is a standard earnings‑date notice with modest relevance for short‑term traders.

03

What to watch

Potential hidden guidance or surprise in the upcoming release could move the stock, but no indication yet.

Relevance 4/10Novelty 3/10Timing: pre‑market on Nov 3

Background

InfuSystem Holdings filed an 8‑K announcing its Q3 2026 earnings release scheduled for Nov 3 before the market opens.

Company-level read

Ticker impact

$INFUNeutralMedium confidence
Context

InfuSystem Holdings announced the date and time for its Q3 2026 earnings release and conference call.

Expected impact

likely modest volatility as traders position for the earnings release

Evidence & confidence

No financial numbers are disclosed; the news is a standard earnings‑date filing, offering limited actionable insight.

Market effects

None beyond the medical device sector awaiting the earnings report.

Limited to US investors tracking the stock.

Low; the filing does not affect broader markets.

Counterpoint

Without new guidance or surprise, the earnings date may be a neutral event; traders could ignore it.

Key entities

  • InfuSystem Holdings

    Medical device company reporting Q3 2026 results.

Related articles

$INFUMed

InfuSystem Announces Financial Results for Third Quarter 2026

InfuSystem Holdings, Inc (INFU) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 InfuSystem Holdings, Inc. 3851 W. Hamlin Road Rochester Hills, MI 48309 (248) 291-1210 Contact: Barry Steele Chief Financial Officer (248) 260-2211 InfuSystem Announces Financial Results for Third Quarter 2026 Investor Conference Call to be held on November 10, 2026

$INFUMed

InfuSystem (INFU) Q2 2026 Earnings Call Transcript

InfuSystem (INFU) reported Q2 2026 revenue of $36.9 million, up 2.6% year over year, including a $1.6 million revenue reduction from a GE Healthcare biomedical services contract restructuring. Adjusted EBITDA rose 7.6% to $8.6 million, with margin at 23.4%. Oncology revenue grew 6.4% and Wound Care rose 154%. The company expects 2026 pro forma revenue growth of 6% to 8% and adjusted EBITDA margin in the low-to-mid 20% range.

$INFUMed

InfuSystem Announces Financial Results for Second Quarter 2026

InfuSystem Holdings, Inc (INFU) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 InfuSystem Holdings, Inc. 3851 W. Hamlin Road Rochester Hills, MI 48309 (248) 291-1210 Contact: Barry Steele Chief Financial Officer (248) 260-2211 InfuSystem Announces Financial Results for Second Quarter 2026 Net Revenues of $36.9 million Representing a 2.6% Increa

$LCIDHighAI 8/10

Lucid Jumps 8% on $1.75 Billion Liquidity Boost Despite Q3 Miss; Rivian Dips, Tesla Little Changed

Lucid Group (LCID) stock rose 8% to $3.90 after announcing a $1.75 billion loan expansion with Saudi Arabia's PIF, boosting liquidity to $3.75 billion. Despite missing Q3 revenue and earnings estimates, investors focused on improved cash burn and extended runway. CEO Silvio Napoli highlighted progress in transformation and cost savings. Rivian (RIVN) and Tesla (TSLA) stocks were little changed.